HPV Vaccine Cutting 90% Cases Cervical Cancer
99% Of Cervical Cancer Are Caused by The Infection from Human Papillomavirus
The initial data report obtained from numerous testing across the world has shown that the human papillomavirus antidote or HPV vaccine is able to cut down cervical cancer cases by about 90%. It has been described by the Cancer Research United Kingdom that the findings are a historical milestone and have been able to show that the HPV vaccine is able to save numerous lives.
HPV vaccine to prevent cancer
About all cervical cancers are generally caused by viral infections, and it is currently being hoped that the HPV vaccine administration would be able to fully eliminate the disease. According to the researchers, the increased rate of success shows that those individuals that have been administered with HPV vaccine would require a fewer amount of cervical smear tests.
The fourth-month common type of cancer in women is cervical cancer throughout the world and has killed more than 300,000 women every single year. About nine out of every 10 mortalities caused by cervical cancer have been reported in middle and low-income nations where there is less amount of access for the screening of cervical cancer. It is being hoped that the administration of the HPV vaccine will have a big impact in underdeveloped nations as compared to the wealthier countries.
As a part of the plan developed by the World Health Organization, more than a hundred nations across the globe are currently trying to eliminate the prevalence of cervical cancer in their general population. In the United Kingdom, young girls between the age of 11 and 13 are administered the HPV vaccine, depending on the location of their residence. From 2019, the vaccine for human papillomavirus is also being administered in young males.
The HPV vaccine is only able to prevent the onset of infection in humans, although it would be unable to get rid of the virus once it is inside the body. The viral infection has become so widespread that the administration of the HPV vaccine has now been aimed to be completed before they become sexually active.
New routine screening test
The research study that has recently been published in The Lancet journal has worked on a prospective study design to check the onset of cervical cancer in girls across England after the initiation of HPV vaccine administration in the year 2008.
The students are currently adults in their late 20s. And the study has been able to show a massive reduction in both of the growths in the pre-cancerous stage and an overall 87% reduction in the onset of cervical cancer, which has been achieved through immunization from human papillomavirus.
One of the researchers who has taken part in the study and is working at King’s College London stated that the impact of the study has proven to be huge. The reduction in the diagnosis of cervical cancer was very less dramatic when older adolescents had been immunized as part of a campaign to catch up.
From the overall study, it has been estimated that the HPV program has been able to prevent the onset of 450 cervical cancers along with 17,200 individuals from pre-cancers. According to Prof Peter Sasieni, this research study regarding the immunization from cervical cancers through the HPV vaccine is only the tip of the iceberg, as those children that had been vaccinated were young to be diagnosed with cancer, so the numbers are likely to further grow over time.
During the current healthcare routine tests, women are generally invited for a routine cervical smear test after every three to five years for the screening of cervical cancer. Although it has been stated by the researcher that there is an urgent requirement to rethink these routine tests after the results from the study on HPV vaccine administration.
It is being hoped that the research study would prove to be a wake-up call for the policymakers, and when women read regarding the study, it would make them think regarding routine screening tests. The new screening program for women of all ages would be formed and should be conducted at least two to three times in a lifetime, while a regular small interval screening test should be conducted for women that have not been administered with the human papillomavirus vaccine.